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ABSTRACT 
Background: Prevention of postoperative pain provides better and more 
rapid convalescence for patients. 
Objective: The aim of this study was to compare the preventive analgesic 
effect of tramadol and lornoxicam in the early postoperative p riod in patients 
undergoing percutaneous nephrolithotomy (PCNL). 
Methods: Patients who were scheduled for elective PCNL at the Cumhuriyet 
University Hospital, Sivas, Turkey, were enrolled in this prospective, double- 
blind, placebo-controlled study. The patients were randomly assigned to 1 of 
3 groups: tramadol, lornoxicam, and normal saline (NS). Ten minutes before 
induction of anesthesia, the tramadol group received tramadol 100 mg IV, the 
lornoxicam group received lornoxicam 8 mg IV, and the NS group received NS 
2 mL IV. Anesthesia was induced using fentanyl 1 1Jg/kg and thiopental sodium 
4 to 7 mg/kg. Vecuronium 0.1 mg/kg was used for muscle relaxation. Desflurane 
4% to 6% and 50%:50% oxygen/nitrous oxide were used for maintenance. Oxy- 
gen saturation, heart rate, and mean blood pressure were recorded before in- 
duction and during the postoperative period. During the postoperative period, 
visual analogue scale O/AS) scores, time to first analgesic (TFA), total analgesic 
consumption (TAC), and patient satisfaction scores were determined. Data 
about postoperative nausea and vomiting and other adverse vents and com- 
plications were also collected. 
Results: Seventy-three patients were assessed for enrollment and 60 (33 women, 
27 men; mean [SD] age, 44.69 [11.27] years; age range, 20-62 years) were in- 
cluded in the study. The baseline demographic characteristics and duration of 
surgery were similar in all 3 groups. The mean (SD) VAS scores in the tramadol 
group were significantly lower than in the NS group at 15 and 30 minutes and 1, 2, 
4, and 12 hours after surgery (all, P < 0.05). The VAS scores in the lornoxicam 
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group were significantly lower than in the NS group at 15 and 30 minutes and 
1 hour (all, P < 0.05). The VAS score at 1 hour after surgery was significantly 
lower in the tramadol group than in the lornoxicam group (18 [8] vs 32 [16]; 
P < 0.05); however, there were no other significant differences in VAS scores 
between the active groups. A significantly shorter TFA was associated with 
the NS group when compared with the tramadol and lornoxicam groups (46 
[27] vs 354 [187] and 180 [118], respectively; both, P < 0.05). TFA was signifi- 
cantly shorter in the lornoxicam group when compared with the tramadol 
group (180 [118] vs 354 [187]; P < 0.05). TAC was significantly higher in the NS 
group than in the tramadol and lornoxicam groups (270 [47] vs 115 [74] and 145 
[72], respectively; both, P < 0.05). Patient satisfaction score (range) was signifi- 
cantly lower in the NS group when compared with the tramadol and lornoxicam 
groups (0 [0-1] vs 3 [0-3] and 2 [0-3], respectively; both, P< 0.05). There were 
no other significant between-group differences observed. 
Conclusions: Tramadol and lornoxicam were more effective than NS in pre- 
venting early postoperative pain. The preventive analgesic effect of tramadol 
was comparable with that of lornoxicam, except at 1 hour when tramadol was 
more effective among these patients undergoing PCNL. Both drugs were well tol- 
erated. (Curt Ther Res Clm Exp. 2007;68:205-216) Copyright © 2007 Excerpta 
Medica, Inc. 
Key words: preventive analgesia, lornoxicam, percutaneous nephrolithotomy, 
tramadol. 
INTRODUCTION 
The concept of preventive analgesia is generally known and often used for post- 
operative pain control. 1-4 Therefore, appropriate postoperative pain treatment 
may start before surgery, last long enough after surgery to avoid pain-induced 
sensitization processes, and include effective analgesic interventions (preventive 
analgesia). The concept of preventive analgesia includes multimodal ntinocicep- 
tive techniques with analgesics that exceed the expected uration of action and 
that attenuate peripheral or central hypersensitivity. 5 
Tramadol is an opioid analgesic widely used in anesthesia and particularly 
suitable for postoperative analgesia. 6,7 It has a lower affinity for opioid recep- 
tors than morphine, resulting in analgesic potency that is 10 times weaker than 
that of morphine, but similar to that of pethidine. The mean elimination tl/2 of 
tramadol is 5 to 6 hours. Furthermore, only 40% of the analgesic effect of tra- 
madol is antagonized by naloxone, suggesting an additional nonopioid mecha- 
nism that contributes to the overall analgesic effect of tramadol. 8 This second 
mechanism is associated with the activation of the descending antinociceptive 
system and consists of both inhibition of the reuptake mechanisms for nor- 
adrenaline and serotonin (5-HT) and increased release of 5-HT. 8-1° 
Lornoxicam is an NSAID that belongs to the enolic acid chemical class, which 
also includes tenoxicam and piroxicam. Its analgesic potency in experimental 
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pain models exceeds that of tenoxicam and piroxicam by -12- and 3-fold, respec- 
tively, and that of diclofenac and indomethacin by 6- and 4-fold, respectively. 11 
Lornoxicam is rapidly eliminated, having a short plasma elimination tl/2 of 3 to 
5 hours, 12,13 which suggests it is suitable for acute use in the postoperative 
period. In the treatment ofpostoperative pain, lornoxicam has been found to be 
as effective as morphine, 14 pethidine, 15 and tramadol. 16 
The aim of this study was to compare the preventive analgesic effect of 
tramadol and lornoxicam in the early postoperative period in patients under- 
going percutaneous nephrolithotomy (PCNL). 
PATIENTS AND METHODS 
Written informed consent was obtained from each patient, and the study proto- 
col was approved by the local human ethics committee. Patients with American 
Society of Anesthesiologists '17 physical status I and II, who were scheduled for 
elective PCNL at the Cumhuriyet University Hospital, Sivas, Turkey, were eligi- 
ble for this prospective, double-blind, placebo-controlled study. Exclusion crite- 
ria were age <18 years, a history of drug or alcohol abuse, chronic use of drugs 
known to alter anesthetic or analgesic requirements, or allergy to any of the 
study medications. Patients were also excluded if they were receiving an experi- 
mental drug, including tramadol or lornoxicam; had a history of gastric, renal, 
cardiac, or respiratory disorder; or >50% above their ideal weight. 
Before surgery, patients were instructed in the use of the 100-mm visual ana- 
logue scale (VAS) for pain assessment (0= no pain to 100 = maximum pain). VAS 
scores were assessed under static conditions in our clinical setting. 
None of the patients was premedicated. On arrival in the operating room, 
patients were administered lactated Ringer's olution 10 mL/kg • h IV after base- 
line measurements of heart rate (HR), noninvasive mean arterial pressure (MAP), 
and oxygen saturation (SpO2) with a Criticare System 1100 monitor (Criticare 
System Inc., Waukesha, Wisconsin). Before induction of anesthesia, patients 
were allocated randomly to receive 1 of the 3 study drugs. Randomization was 
based on a computer-generated co e that was prepared at a remote site and 
sealed in opaque, sequentially numbered envelopes. Randomization was based 
on blocks of 6 patients. The drugs were prepared by an anesthetist (who was 
not one of the study investigators) in three 2-mL syringes, which contained 
either tramadol hydrochloride 100 mg (Contramal, Grfinenthal GmbH, Aachen, 
Germany), lornoxicam 8 mg (Xefo, Mefar Ilac Sanayii A.S., Istanbul, Turkey), or 
normal saline (NS) 2 mL. They were marked only with a coded label to maintain 
the double-blind nature of the study. Ten minutes before induction of anesthe- 
sia the appropriate study drug was administered. 
Anesthesia was induced using fentanyl 1 1Jg/kg (Fentanyl citrate injection, 
Abbott Laboratories, North Chicago, Illinois) and thiopental sodium 4 to 
7 mg/kg (Pental Sodyum, I.E. Ulagay Ilac Sanayii Turk A.S., Istanbul, Turkey). 
Vecuronium 0.1 mg/kg (Norcuron, Organon-Teknika, Boxtel, The Netherlands) 
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was used for muscle relaxation and maintained (0.03 mg/kg) by bolus administra- 
tion at 30-minute intervals. Desflurane 4% to 6% (Suprane, Eczac]basi-Baxter 
Hastane Urunleri San. ve Tic. A.S., Istanbul, Turkey) and 50%:50% oxygen/nitrous 
oxide were used for maintenance. No opioids were administered intraoperatively. 
Recovery was assessed using the objective criteria of the modified Aldrete 
scoring recommendat ions.  18 Each variable was scored on a 3-point sca le - -  
consc iousness (2 = fully awake; 1 = able to be roused on calling; 0 = not respond- 
ing), activity (able to move voluntari ly or on command;  2 = 4 extremities, 1 = 
2 extremities; 0 = 0 extremities), respiration (2 = able to breathe deeply and 
cough freely; 1 = dyspnea, shallow or limited breathing; 0 = apneic), circulation 
(2 = blood pressure [BP] _+<20 mm of preanesthet ic  level; 1 = BP _+20-50 mm of 
preanesthet ic  level; 0 = BP _+>50 mm of preanesthet ic  level), and SpO 2 (2 = >92% 
on room air; 1 = needs 02 inhalation to maintain SpO 2 >90%; 0 = SpO 2 <90% 
even with 02 supp lementat ion) - -w i th  a max imum achievable score of 10. 
After total  recovery  from anesthes ia  (Aldrete score _>9), pat ients  were trans-  
ferred to the recovery  room for _>1 hour and were then discharged to the ward. 
HR, MAP, and SpO 2 were recorded before induction of anesthesia.  VAS, HR, MAP, 
and SpO 2 were recorded at 15 and 30 minutes, and at 1, 2, 4, 6, 12, and 24 hours, 
postoperat ively.  
Aldrete scores were recorded at 1, 15, and 30 minutes after extubation. 
Tramadol  50 mg IV was administered either at the patient 's request or when the 
VAS score was >30 mm, and was repeated if the VAS score remained >30 mm. 
Time to first analgesic (TFA) and total analgesic consumpt ion (TAC) were 
recorded at 24 hours. All patients were asked to rate their degree of satisfaction 
with the management  of their pain (0 = poor; 1 = adequate; 2 = good; 3 = excel- 
lent) on a quest ionnaire administered after the study period. Pr imary efficacy 
assessment  included the proport ion of patients with successful analgesia, 
defined as no or mild pain with a respi ratory rate of _>11/min and an SpO 2 of 
_>94% for the entire per iod after administ rat ion of the s tudy  drugs and with 
an excellent degree of satisfaction. Frequency of nausea, vomiting, and other 
adverse events (AEs) were recorded postoperatively.  
The pr imary  outcomes in this s tudy were VAS, TFA, TAC, and patient satisfac- 
tion score. Secondary outcomes in this s tudy were hemodynamic  and respira- 
tory  variables and AEs. 
Statistical Analysis 
Data are presented as mean (SD), median (range), or percentage, as appro- 
priate. Statistical analyses were performed using Statistica 7.0 software 
(Statsoft, Inc., Tulsa, Arizona). Demographic variables, TFA, and TAC among the 
groups were compared using 1-way analysis of variance (ANOVA). The ratio of 
male/female patients and the prevalence of nausea and vomiting in the study 
groups were compared using the Z 2 test. VAS scores were analyzed using 
Friedman's nonparametric repeated-measures ANOVA. HR, MAP, and SpO 2 
among the groups were compared using repeated-measures ANOVA. Patient sat- 
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isfaction scores in the study groups were compared using Kruskal-Wallis 1-way 
ANOVA. All post hoc comparisons were performed using the Tukey test. P< 0.05 
was considered statistically significant. 
Using ANOVA to determine sample size, a mean difference of 15 mm on the 
100-mm VAS used for pain assessment at 15 minutes postoperatively was defined 
as clinically relevant in all groups. It was expected that 95% of the reported VAS 
scores would range between 0 and 80 mm, resulting in an SD of 17 mm. A total 
sample size of 54 patients (18 in each arm of the study) was calculated to be nec- 
essary to detect a 15-mm reduction in VAS score with a power of 80% and an cc 
error of 5%. It was assumed that the study dropout rate would be -20%, and 
therefore a total sample of 66 patients was needed. 
RESULTS 
During the study period between June 2005 and March 2006, 73 consecutive pa- 
tients with the required PCNL indication were identified. Two had to be excluded 
because of obesity, 3 refused to participate, and 2 were missed because of high 
workload. Therefore, 66 patients were identified as suitable for the study and were 
randomly assigned to 1 of the 3 groups. Of these 66 patients, 2 in each of the 
groups had to be excluded from data analysis because of protocol violations. 
Therefore, 60 patients (33 women, 27 men; mean [SD] age, 44.69 [11.27] years; age 
range, 20-62 years) completed the study and were included in the data analyses. 
There were no significant differences between the tramadol, lornoxicam, and 
NS groups with regard to age, sex, weight, or the duration of surgery (Table). 
There also were no statistically significant differences in hemodynamic data 
(MAP and HR) or in SpO 2 values at the induction of anesthesia or during the 
postoperat ive period. These values remained within the normal range through- 
Table. Baseline demographic characteristics and duration of surgery of the study 
patients undergoing percutaneous nephrolithotomy (n -- 60). Data are mean 
(SD) unless otherwise specified.* 
Characteristic 
Tramadol Lornoxicam Normal Saline 
Group Group Group 
(n = 20) (n = 20) (n = 20) 
Age, y 43.66 (11.43) 43.86 (13.42) 46.53 (9.11) 
Sex, no. (%) 
Female 10 (50) 12 (60) 11 (55) 
Male 10 (50) 8 (40) 9 (45) 
Weight, kg 72.4 (6.3) 70.6 (10.1) 76.0 (8.7) 
Duration of surgery, rain 121.66 (45.34) 108.66 (30.67) 119.50 (29.91) 
*There were no significant between-group differences. 
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out the study period. Median (range) Aldrete scores for the tramadol, lornoxi- 
cam, and NS groups within 1 minute after extubation were 9 (7-9), 9 (7-9), and 
8 (6-9), respectively. All patients in the 3 groups had Aldrete scores of 9 at 15 
and 30 minutes after extubation. 
The mean (SD) VAS scores in the tramadol group were significantly lower 
than in the NS group at 15 and 30 minutes and 1, 2, 4, and 12 hours after surgery 
(all, P < 0.05). The VAS scores in the lornoxicam group were significantly lower 
than in the NS group at 15 and 30 minutes and 1 hour (all, P < 0.05). The VAS 
score was significantly lower in the tramadol group than in the lornoxicam group 
at 1 hour (18 [8] vs 32 [16]; P< 0.05) (Figure 1). There were no other signifi- 
cant differences in VAS scores between the active drug groups. 
Mean (SD) TFA was significantly shor ter  in the NS group than in the tra- 
madol and lornoxicam groups (46 [27] vs 354 [187] and 180 [118] minutes, 
respectively; both, P < 0.05). TFA was significantly shor ter  in the lornoxicam 
group than in the tramadol  group (180 [118] vs 354 [187] minutes; P < 0.05) 
(Figure 2). 
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Figure 1. Reported mean (SD) visual analogue scale (VAS) scores by study group in 
patients after percutaneous nephrol i thotomy. *P < 0.05 versus normal saline; 
tp < 0.05 versus Iornoxicam. Scale: 0 = no pain to 100 = maximum pain. 
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Figure 2. 
,<, 
a 
e- 
550 
500 
450 
400 
350 
300 
250 
200 
150 
100 
50 
0 
* t  
T 
I I 
I I I 
Tramadol Lornoxicam Normal 
Saline 
Mean (SD) time to first analgesic (TFA) by study group in patients under- 
going percutaneous nephrolithotomy. *P < 0.05 versus normal saline; tp < 0.05 
versus tramadol. 
Mean (SD) TAC was significantly higher in the NS group than in the tramadol 
and lornoxicam groups (270 [47] vs 115 [74] and 145 [72] mg, respectively; 
both, P < 0.05) (Figure 3). There were no significant differences in TAC between 
the active drug groups. 
The mean (range) patient satisfaction score in the NS group was significantly 
lower than in the tramadol and lornoxicam groups (0 [0-1] vs 3 [0-3] and 2 [0-3], 
respectively; both, P < 0.05) (Figure 4). There were no significant differences in
patient satisfaction scores between the active drug groups. 
There were no significant differences in the prevalence or proportion 
of patients with nausea and vomiting in the tramadol, lornoxicam, and NS 
groups (33%, 30%, and 40%, respectively). There were no other observed AEs 
or complications. 
DISCUSSION 
We found that the effects of tramadol and lornoxicam were comparable with 
regard to HR, SpO2, MAP, and AEs at the induction of anesthesia and during the 
postoperative period. During the postoperative period, the analgesic effect of 
tramadol and lornoxicam was significantly higher than that of NS. The analgesic 
effect of tramadol was significantly greater than that of lornoxicam only at 1 hour 
postoperatively; there were no other significant differences between the active 
groups at other time points. TFA was significantly longer in patients adminis- 
tered tramadol and lornoxicam than NS, and TFA was also significantly longer 
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with tramadol than with lornoxicam. TAC and patient satisfaction score were 
comparable in the tramadol and lornoxicam groups. Our results uggest that tra- 
madol and lornoxicam were more effective and as well tolerated as NS when 
used as a preventive analgesic administered before general anesthesia for PCNL. 
Schug et a119 suggested that 20% to 40% of patients experience postoperative 
pain of moderate intensity and another 50% to 70% experience severe postop- 
erative pain. Postoperative pain not only causes considerable distress to the 
patient, but it also contributes to prolonging recovery time and may adversely 
affect patient outcome. 2°
Tramadol is a p-opioid receptor agonist hat inhibits serotonin and norepi- 
nephrine reuptake, enhancing inhibitory effects on pain transmission i  the 
spinal cord. 8 Lornoxicam inhibits cyclooxygenase enzymes and decreases 
peripheral and central prostaglandin production. 11,12 In addition to reducing the 
inflammation that accompanies tissue injury, decreasing prostaglandin produc- 
tion attenuates the response of the peripheral and central components of the 
nervous ystem to noxious stimuli. 11,12 The flow of nociceptive information in 
the perioperative period is biphasic. The first phase is directly connected with 
nociceptive stimulation that accompanies injuries brought about by surgical 
procedures. The second phase, manifesting itself in the postoperative p riod, is 
the result of inflammatory esponses associated with this injury and is caused 
by the first-phase changes in nociceptive structures of the spinal cord. 11,12 The 
aim of preventive analgesia is to prevent or inhibit the first phase and thus to 
protect he central nervous ystem from increased noxious stimulation during 
surgery. 21,22 Several studies 1-4 of preventive analgesia found that preoperative 
administration f systemic opioids was more effective in reducing postoperative 
pain than in control conditions (placebo use or preoperative use of study drugs). 
Therefore, in this study we administered the study drugs before the induction of 
anesthesia. 
Although opioid analgesics are the traditional first-line treatment in this set- 
ting, 19 they have the potential to cause AEs such as respiratory depression, con- 
fusion, drowsiness, nausea, and vomiting, which often lead to a reluctance to 
increase doses to achieve adequate analgesia. 23NSAIDs provide effective anal- 
gesia in patients with acute pain after minor and major surgery, either as a sub- 
stitute for, or as an adjunct o, opioid analgesia. 23,24 The major advantage of 
NSAIDs is that, compared with opioid analgesics, they are relatively well toler- 
ated when used in selected patients for short-term postoperative analgesia. 25
Tramadol, which possesses bidirectional action via opioid receptors and 
activation of the descending antinociceptive system, used as preemptive anal- 
gesia may successfully inhibit the development of the nociceptive process and 
its consequences in the perioperative period. This has been suggested in experi- 
mental and clinical observations 26 of the effect of preemptive analgesia induced 
by drugs activating the noradrenergic and serotoninergic systems, indicating 
that not only opioids but drugs that activate the descending antinociceptive 
system may inhibit central sensitization. 
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In a prospective, randomized, double-blind study, Naguib et a127 compared 
the efficacy of tramadol and morphine for intra- and postoperative analgesia in 
100 patients undergoing laparoscopic holecystectomy. Ten minutes before 
induction of anesthesia, patients received tramadol 100 mg or morphine 10 mg IV. 
They reported no significant difference between the use of tramadol and mor- 
phine to treat pain. The prospective, randomized, ouble-blind, controlled study 
by Unlugenc et al 6 suggested that in patients who underwent major abdominal 
surgery, tramadol 1mg/kg administered after induction of anesthesia was associ- 
ated with postoperative pain relief, recovery, and patient-controlled analgesia 
morphine consumption similar to patients administered morphine 0.1 mg/kg. 
Wordliczek et al 7 investigated the influence of preemptive IV tramadol admin- 
istered before general anesthesia in 90 patients, immediately after peritoneal 
closure, or immediately after surgery on the tramadol requirement in the first 
24 hours after surgery. They concluded that the pre- or intraoperative use of 
tramadol significantly reduced the opioid requirement in the early postopera- 
tive period, confirming the possibility that tramadol used in this way may 
inhibit the activation of sensitization processes connected with Phase I of noci- 
ceptive information flow. In our study, after the administration f tramadol as a 
preventive analgesic agent, the early postoperative analgesic requirement was 
significantly ower than those of lornoxicam and NS. 
Preoperative cyclooxygenase inhibitors had clear benefits in terms of reduced 
postoperative pain and analgesic onsumption and increased patient satisfac- 
tion compared with placebo. 3 Effects on postoperative nausea and vomiting 
remain uncertain, as do those on recovery from surgery or economic benefit. 3 
Beneficial effects have been reported with NSAIDs in orthopedic surgery 28 and 
during laparoscopic tubal ligation. 29 In contrast, other authors have reported 
no benefit of preoperative administration f NSAIDs on postoperative analgesia 
after orthopedic or laparoscopic gynecologic surgery. 4,3°,31 In the present study, 
preoperative administration of lornoxicam relieved pain after PCNL signifi- 
cantly more effectively than NS and similar to tramadol, except at 1 hour when 
tramadol was significantly more effective. 
We believe that the major limitation of this study was the possible analgesic 
contribution of the general anesthesia agents used. 
CONCLUSIONS 
Tramadol and lornoxicam were more effective than NS in preventing early post- 
operative pain. The preventive analgesic effect of tramadol was comparable to 
that of lornoxicam, except at 1 hour, when tramadol was more effective among 
these patients undergoing PCNL. Both drugs were well tolerated. 
REFERENCES 
1. Lavand'homme P, De Kock M, Waterloos H. Intraoperative epidural analgesia com- 
bined with ketamine provides effective preventive analgesia in patients undergoing 
major digestive surgery. Anesthesiology. 2005;103:813-820. 
214 
Kaygusuz et aL 
2. Menigaux C, Adam F, Guignard B, et al. Preoperative gabapentin decreases anxiety 
and improves early functional recovery from knee surgery. Anesth Analg. 2005;100: 
1394-1399. 
3. Straube S, Derry S, McQuay H J, Moore RA. Effect of preoperative Cox-II-selective 
NSAIDs (coxibs) on postoperative outcomes: A systematic review of randomized 
studies. Acta Anaesthesiol Scand. 2005;49:601-613. 
4. Boccara G, Chaumeron A, Pouzeratte Y, Mann C. The preoperative administration of
ketoprofen improves analgesia fter laparoscopic cholecystectomy in comparison 
with propacetamol r postoperative k toprofen. Br JAnaesth. 2005;94:347-351. 
5. Pogatzki-Zahn EM, Zahn PK. From preemptive to preventive analgesia. Curr Opin 
Anaesthesiol. 2006;19:551-555. 
6. Unlugenc H, Ozalevli M, Gunes Y, et al. Pre-emptive analgesic efficacy of tramadol com- 
pared with morphine after major abdominal surgery. Br J Anaesth. 2003;91:209-213. 
7. Wordliczek J, Banach M, Garlicki J, et al. Influence of pre- or intraoperational use of 
tramadol (preemptive or preventive analgesia) on tramadol requirement in the early 
postoperative p riod. Pol J Pharmacol. 2002;54:693-697. 
8. Raffa RB, Friderichs E, Reimann W, et al. Opioid and nonopioid components inde- 
pendently contribute to the mechanism of action of tramadol, an "atypical" opioid 
analgesic. J Pharmacol Exp Ther. 1992;260:275-285. 
9. Bamigbade TA, Davidson C, Langford RM, Stamford JA. Actions of tramadol, its enan- 
tiomers and principal metabolite, O-desmethyltramadol, on serotonin (5-HT) efflux 
and uptake in the rat dorsal raphe nucleus. Br J Anaesth. 1997;79:352-356. 
10. Driessen B, Reimann W, Giertz H. Effects of the central analgesic tramadol on the 
uptake and release of noradrenaline and dopamine in vitro. Br J Pharmacol. 1993; 108: 
806-811. 
11. Pruss TP, Stroissnig H, Radhofer-Welte S, et al. Overview of the pharmacological 
properties, pharmacokinetics and animal safety assessment of lornoxicam. Postgrad 
Med J. 1990;66(Suppl 4):$18-$21. 
12. Hitzenberger G,Radhofer-Welte S, Takacs F, Rosenow D. Pharmacokinetics of lornoxi- 
cam in man. Postgrad Med J. 1990;66(Suppl 4):$22-$27. 
13. Olkkola KT, Brunetto AV, Mattila MJ. Pharmacokinetics of oxicam nonsteroidal nti- 
inflammatory agents. Clin Pharmacokinet. 1994;26:107-120. 
14. Norholt SE, Sindet-Pedersen S, Larsen U, et al. Pain control after dental surgery: A 
double-blind, randomised trial of lornoxicam versus morphine. Pain. 1996;67:335-343. 
15. Rosenow DE, Van Krieken F, Stolke D, Kursten FW. Intravenous administration of
lornoxicam, a new NSAID, and pethidine for postoperative pain: A placebo- 
controlled pilot study. Clin Drug Invest. 1996; 11:11-19. 
16. Ilias W, Jansen M. Pain control after hysterectomy: An observer-blind, randomised 
trial of lornoxicam versus tramadol. Br J Clin Pract. 1996;50:197-202. 
17. Fleisher LA. Risk of anesthesia. In: Miller RD, ed. Miller's Anesthesia. 6th ed. 
Philadelphia, Pa: Elsevier; 2005:893-925. 
18. Aldrete JA. The post-anesthesia recovery score revisited. J Clin Anesth. 1995;7:89-91. 
19. Schug SA, Merry AF, Acland RH. Treatment principles for the use of opioids in pain 
of nonmalignant origin. Drugs. 1991;42:228-239. 
20. Agency for Health Care Policy and Research. Acute pain management: Operative or 
medical procedures and trauma, Part 1. Clin Pharm. 1992;11:309-331. 
21. Katz J, Kavanagh BP, Sandier AN, et al. Preemptive analgesia. Clinical evidence of 
neuroplasticity contributing to postoperative pain. Anesthesiology. 1992;77:439-446. 
215 
CURRENT THERAPEUTIC RESEARCH 
22. Kissin I. Preemptive analgesia. Anesthesiology. 2000;93:1138-1143. 
23. Nuutinen LS, Laitinen JO, Salomaki TE. A risk-benefit appraisal of injectable NSAIDs 
in the management of postoperative pain. Drug Saf. 1993;9:380-393. 
24. Moote C. Efficacy of nonsteroidal anti-inflammatory drugs in the management of
postoperative pain. Drugs. 1992;44(Suppl 5):14-29; discussion 29-30. 
25. Kehlet H, Dahl JB. Are perioperative nonsteroidal anti-inflammatory drugs ulcero- 
genic in the short term? Drugs. 1992;44(Suppl 5):38-41. 
26. Wordliczek J, Banach M, Dorazil M, Przewlocka B. Influence of doxepin used in pre- 
emptive analgesia on the nociception in the perioperative period. Experimental nd 
clinical study. Pol J Pharmacol. 2001;53:253-261. 
27. Naguib M, Seraj M, Attia M, et al. Perioperative antinociceptive effects of tramadol. 
A prospective, randomized, double-blind comparison with morphine. Can JAnaesth. 
1998;45:1168-1175. 
28. Fletcher D. Prevention of postoperative pain [in French]. Ann FrAnesth Reanim. 1998; 
17:622-632. 
29. Eriksson H. Effect of intravenous ketoprofen on pain after outpatient laparoscopic 
sterilisation. Acta Anaesthesiol Scand. 1995;39:975-978. 
30. Buggy D J, Wall C, Carton EG. Preoperative or postoperative diclofenac for laparo- 
scopic tubal ligation. Br JAnaesth. 1994;73:767-770. 
31. Vanlersberghe C, Lauwers MH, Camu E Preoperative ketorolac administration has no 
preemptive analgesic effect for minor orthopaedic surgery. Acta Anaesthesiol Scand. 
1996;40:948-952. 
Address correspondence to: Kenan Kaygusuz, MD, Department  of Anesthesi- 
ology, Cumhuriyet University School of Medicine, 58140 Sivas, Turkey. E-mail: 
kaygusuzkenan@gmail .com 
216 
